NASDAQ:APYXApyx Medical Stock Price, Forecast & News

Apyx Medical's stock was trading at $5.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, APYX stock has decreased by 19.6% and is now trading at $4.07. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Apyx Medical.

Apyx Medical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Apyx Medical.

Apyx Medical Corp (NASDAQ:APYX) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.05. The business earned $5 million during the quarter, compared to the consensus estimate of $5.29 million. Apyx Medical had a negative return on equity of 21.45% and a negative net margin of 58.26%. View Apyx Medical's earnings history.

Apyx Medical issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, March, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5-5.6 million, compared to the consensus revenue estimate of $7.82 million.

2 analysts have issued twelve-month price targets for Apyx Medical's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Apyx Medical's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View analysts' price targets for Apyx Medical.

News headlines about APYX stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apyx Medical earned a news sentiment score of -4.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutApyx Medical.

Apyx Medical saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 368,900 shares, a decline of 22.7% from the April 30th total of 477,400 shares. Based on an average trading volume of 101,200 shares, the days-to-cover ratio is currently 3.6 days. Approximately 1.3% of the company's stock are short sold. View Apyx Medical's Current Options Chain.

Some companies that are related to Apyx Medical include Vapotherm (VAPO), LeMaitre Vascular (LMAT), SI-Bone (SIBN), SurModics (SRDX), Co-Diagnostics (CODX), Anika Therapeutics (ANIK), Antares Pharma (ATRS), Repro-Med Systems (REPR), Repro Med Systems (KRMD), MiMedx Group (MDXG), AngioDynamics (ANGO), Intersect ENT (XENT), Cytosorbents (CTSO), Utah Medical Products (UTMD) and SeaSpine (SPNE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), Procter & Gamble (PG), AT&T (T), Wells Fargo & Co (WFC), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP).

Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."

Apyx Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.55%), State Street Corp (1.75%), Taylor Frigon Capital Management LLC (1.42%), Geode Capital Management LLC (1.22%), Taylor Frigon Capital Management LLC (1.20%) and Cowen AND Company LLC (1.04%). View institutional ownership trends for Apyx Medical.

APYX stock was sold by a variety of institutional investors in the last quarter, including Silvercrest Asset Management Group LLC, Millrace Asset Group Inc., Morgan Stanley, Cowen Prime Services LLC, State Street Corp, Taylor Frigon Capital Management LLC, and Quilter Plc. View insider buying and selling activity for Apyx Medical.

APYX stock was acquired by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, JPMorgan Chase & Co., Taylor Frigon Capital Management LLC, Wells Fargo & Company MN, Geode Capital Management LLC, State Board of Administration of Florida Retirement System, Engineers Gate Manager LP, and SG Americas Securities LLC. View insider buying and selling activity for Apyx Medical.

Shares of APYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APYX stock can currently be purchased for approximately $4.07.

Apyx Medical has a market capitalization of $139.11 million and generates $28.15 million in revenue each year. The company earns $-19,710,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Apyx Medical employs 222 workers across the globe.

The official website for Apyx Medical is www.apyxmedical.com.

Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The company can be reached via phone at 727-384-2323 or via email at [email protected]